

4 May 2022

Botanix Investor Webinar

Philadelphia PA and Perth Australia, 4 May 2022: Clinical dermatology company, Botanix Pharmaceuticals Limited (ASX: BOT, “Botanix” or “the Company”), will be hosting an investor webinar **today, Wednesday 4th May 2022 at 9:00am (Perth), 11:00am (Sydney/Melbourne)** to update shareholders following the announcement that it has successfully completed the acquisition of Sofpironium Bromide, the first and only novel treatment for *primary axillary hyperhidrosis* - a medical condition which results in excessive underarm sweating.

The webinar will be hosted by Botanix’s President and Executive Chairman, Vince Ippolito, Executive Director Matt Callahan, Chief Medical Adviser, Dr Patricia Walker and Chief Commercial Officer, Howie McKibbin.

Webinar details

Date: Wednesday 4th May 2022

Time: 9:00am AWST (Perth), 11:00am AEST (Sydney/Melbourne)

To register: https://us02web.zoom.us/webinar/register/WN_N6Q_QtS_TV-rpfjKXfTpeA

Dial in details: Will be provided to you upon registration

Shareholders will be able to submit questions during the webinar via a written Q&A facility displayed at the bottom of the webinar screen, or can submit them in advance to hhowlett@we-worldwide.com.

Release authorised by

Vince Ippolito

President and Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (USA) which is committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has a mature dermatology pipeline with its first product, Sofpironium Bromide for the treatment of primary axillary hyperhidrosis planned to be filed for FDA in 2H 2022, and a series of other products

in late-stage clinical studies for the treatment of rosacea, dermatitis and acne. Botanix is also developing a topical antimicrobial product for the eradication of bacteria, initially in patients undergoing hemodialysis.

Botanix leverages its proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which is utilised in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

H^CK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.